Similarly, when restricting the analysis to grade 4 gliomas, a significantly shorter PFS was noted in the group with a higher change in ACTA2 expression (high change group (n = 4): median 5 months (range: 4–7); low change group (n = 3): median 17 months (range: 10–31)) (Figure 5B, p = 0.017). The gene discussed is ACTA2; the disease is central nervous system cancer.